Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment

Raymond Niaura, Bonnie Spring, Belinda Borrelli, Donald Hedeker, Michael G. Goldstein, Nancy Keuthen, Judy Depue, Jean Kristeller, Judy Ockene, Allan Prochazka, John A. Chiles, David Abrams

Research output: Contribution to journalArticle

Abstract

The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.

Original languageEnglish (US)
Pages (from-to)887-896
Number of pages10
JournalJournal of Consulting and Clinical Psychology
Volume70
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Withholding Treatment
Fluoxetine
Smoking Cessation
Multicenter Studies
Cognitive Therapy
Therapeutics
Smoking
Placebos

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. / Niaura, Raymond; Spring, Bonnie; Borrelli, Belinda; Hedeker, Donald; Goldstein, Michael G.; Keuthen, Nancy; Depue, Judy; Kristeller, Jean; Ockene, Judy; Prochazka, Allan; Chiles, John A.; Abrams, David.

In: Journal of Consulting and Clinical Psychology, Vol. 70, No. 4, 2002, p. 887-896.

Research output: Contribution to journalArticle

Niaura, R, Spring, B, Borrelli, B, Hedeker, D, Goldstein, MG, Keuthen, N, Depue, J, Kristeller, J, Ockene, J, Prochazka, A, Chiles, JA & Abrams, D 2002, 'Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment', Journal of Consulting and Clinical Psychology, vol. 70, no. 4, pp. 887-896. https://doi.org/10.1037//0022-006X.70.4.887
Niaura, Raymond ; Spring, Bonnie ; Borrelli, Belinda ; Hedeker, Donald ; Goldstein, Michael G. ; Keuthen, Nancy ; Depue, Judy ; Kristeller, Jean ; Ockene, Judy ; Prochazka, Allan ; Chiles, John A. ; Abrams, David. / Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. In: Journal of Consulting and Clinical Psychology. 2002 ; Vol. 70, No. 4. pp. 887-896.
@article{70c974f416bc49449effb3df7263a786,
title = "Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment",
abstract = "The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.",
author = "Raymond Niaura and Bonnie Spring and Belinda Borrelli and Donald Hedeker and Goldstein, {Michael G.} and Nancy Keuthen and Judy Depue and Jean Kristeller and Judy Ockene and Allan Prochazka and Chiles, {John A.} and David Abrams",
year = "2002",
doi = "10.1037//0022-006X.70.4.887",
language = "English (US)",
volume = "70",
pages = "887--896",
journal = "Journal of Consulting and Clinical Psychology",
issn = "0022-006X",
publisher = "American Psychological Association Inc.",
number = "4",

}

TY - JOUR

T1 - Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment

AU - Niaura, Raymond

AU - Spring, Bonnie

AU - Borrelli, Belinda

AU - Hedeker, Donald

AU - Goldstein, Michael G.

AU - Keuthen, Nancy

AU - Depue, Judy

AU - Kristeller, Jean

AU - Ockene, Judy

AU - Prochazka, Allan

AU - Chiles, John A.

AU - Abrams, David

PY - 2002

Y1 - 2002

N2 - The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.

AB - The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.

UR - http://www.scopus.com/inward/record.url?scp=0036330654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036330654&partnerID=8YFLogxK

U2 - 10.1037//0022-006X.70.4.887

DO - 10.1037//0022-006X.70.4.887

M3 - Article

VL - 70

SP - 887

EP - 896

JO - Journal of Consulting and Clinical Psychology

JF - Journal of Consulting and Clinical Psychology

SN - 0022-006X

IS - 4

ER -